Bora Pharmaceuticals Co (保瑞藥業) is still looking at contract development and manufacturing organizations (CDMOs) as potential merger and acquisition (M&A) targets, as the company continues to expand its business scale, the medicine and healthcare product maker said yesterday.
The company has seen its market value surge by more than 50-fold in seven years through a series of strategic M&As, including acquiring Japan-based Eisai Co’s subsidiary and plant in Tainan’s Guantian District (官田) in 2013 and US-based Impax Laboratories Inc’s subsidiary and plant in Miaoli County’s Jhunan Township (竹南) in 2018.
“We expect to see new M&A opportunities emerge next year,” Chinese-language online news outlet Cnyes.com quoted Bora Pharmaceuticals chairman Bobby Sheng (盛保熙) as saying. “There are not many buyers in the US M&A market and the valuations of many CDMOs are much cheaper than before, which is relatively beneficial to us.”
Photo: CNA
Sheng made the remarks at a ceremony at the Taiwan Stock Exchange (TWSE), where the company made its share debut on the main board after transferring its listing from the Taipei Exchange.
Bora Pharmaceuticals shares fell 3.1 percent to close at NT$657, in line with losses across the main exchange. Prior to yesterday, the stock had surged more than 60 percent since the beginning of this year.
Due to the growing market demand for drugs, several major clients have already discussed placing more orders, Bora Pharmaceuticals said.
As a result, the company has furthered its acquisition efforts, including factories, companies and product portfolios, it said.
It would also continue to adjust product strategy at its subsidiary TWi Pharmaceuticals Inc (安成藥) in a bid to diversify away from generic drugs, after the unit in August acquired six brand product licenses and technologies from Morristown, New Jersey-based Almatica Pharma Inc, it said.
The new strategy would enable Bora to leverage its sales platforms to enter the brand product market, create a new revenue driver and improve its profit margin, as well as allow the company to have more resources for future investment, it said.
Bora Pharmaceuticals’ consolidated revenue grew 50.25 percent year-on-year to NT$13.25 billion (US$422.5 million) in the first 11 months of this year, ranking second among Taiwanese pharmaceutical companies, TWSE data showed.
Net profit in the first three quarters totaled NT$2.47 billion, up 149.43 percent from the same period last year, with earnings per share rising from NT$10.12 to NT$24.63 and gross margin improving from 35.02 percent to 48.16 percent, the data showed.
China’s Huawei Technologies Co (華為) plans to start mass-producing its most advanced artificial intelligence (AI) chip in the first quarter of next year, even as it struggles to make enough chips due to US restrictions, two people familiar with the matter said. The telecoms conglomerate has sent samples of the Ascend 910C — its newest chip, meant to rival those made by US chipmaker Nvidia Corp — to some technology firms and started taking orders, the sources told Reuters. The 910C is being made by top Chinese contract chipmaker Semiconductor Manufacturing International Corp (SMIC, 中芯) on its N+2 process, but a lack
TECH BOOST: New TSMC wafer fabs in Arizona are to dramatically improve US advanced chip production, a report by market research firm TrendForce said With Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) pouring large funds into Arizona, the US is expected to see an improvement in its status to become the second-largest maker of advanced semiconductors in 2027, Taipei-based market researcher TrendForce Corp (集邦科技) said in a report last week. TrendForce estimates the US would account for a 21 percent share in the global advanced integrated circuit (IC) production market by 2027, sharply up from the current 9 percent, as TSMC is investing US$65 billion to build three wafer fabs in Arizona, the report said. TrendForce defined the advanced chipmaking processes as the 7-nanometer process or more
NVIDIA PLATFORM: Hon Hai’s Mexican facility is to begin production early next year and a Taiwan site is to enter production next month, Nvidia wrote on its blog Hon Hai Precision Industry Co (鴻海精密), the world’s biggest electronics manufacturer, yesterday said it is expanding production capacity of artificial intelligence (AI) servers based on Nvidia Corp’s Blackwell chips in Taiwan, the US and Mexico to cope with rising demand. Hon Hai’s new AI-enabled factories are to use Nvidia’s Omnivores platform to create 3D digital twins to plan and simulate automated production lines at a factory in Hsinchu, the company said in a statement. Nvidia’s Omnivores platform is for developing industrial AI simulation applications and helps bring facilities online faster. Hon Hai’s Mexican facility is to begin production early next year and the
Who would not want a social media audience that grows without new content? During the three years she paused production of her short do-it-yourself (DIY) farmer’s lifestyle videos, Chinese vlogger Li Ziqi (李子柒), 34, has seen her YouTube subscribers increase to 20.2 million from about 14 million. While YouTube is banned in China, her fan base there — although not the size of YouTube’s MrBeast, who has 330 million subscribers — is close to 100 million across the country’s social media platforms Douyin (抖音), Sina Weibo (新浪微博) and Xiaohongshu (小紅書). When Li finally released new videos last week — ending what has
RSS